Kaiser Permanente Northern California, Oakland, and Blood Systems Research Institute and University of California, San Francisco, San Francisco, California (N.H.R.).
Blood Systems Research Institute and University of California, San Francisco, San Francisco, California (E.L.M.).
Ann Intern Med. 2019 Jan 15;170(2):81-89. doi: 10.7326/M17-3253. Epub 2018 Dec 18.
Randomized clinical trial findings support decreased red blood cell (RBC) transfusion and short-term tolerance of in-hospital anemia. However, long-term outcomes related to changes in transfusion practice have not been described.
To describe the prevalence of anemia at and after hospital discharge and associated morbidity and mortality events.
Retrospective cohort study.
Integrated health care delivery system with 21 hospitals serving 4 million members.
445 371 surviving adults who had 801 261 hospitalizations between January 2010 and December 2014.
Hemoglobin levels and RBC transfusion, rehospitalization, and mortality events within 6 months of hospital discharge. Generalized estimating equations were used to examine trends over time, accounting for correlated observations and patient-level covariates.
From 2010 to 2014, the prevalence of moderate anemia (hemoglobin levels between 7 and 10 g/dL) at hospital discharge increased from 20% to 25% (P < 0.001) and RBC transfusion declined by 28% (39.8 to 28.5 RBC units per 1000 patients; P < 0.001). The proportion of patients whose moderate anemia had resolved within 6 months of hospital discharge decreased from 42% to 34% (P < 0.001), and RBC transfusion and rehospitalization within 6 months of hospital discharge decreased from 19% to 17% and 37% to 33%, respectively (P < 0.001 for both). During this period, the adjusted 6-month mortality rate decreased from 16.1% to 15.6% (P = 0.004) in patients with moderate anemia, in parallel with that of all others.
Possible unmeasured confounding.
Anemia after hospitalization increased in parallel with decreased RBC transfusion. This increase was not accompanied by a rise in subsequent RBC use, rehospitalization, or mortality within 6 months of hospital discharge. Longitudinal analyses support the safety of practice recommendations to limit RBC transfusion and tolerate anemia during and after hospitalization.
National Heart, Lung, and Blood Institute.
随机临床试验结果支持减少红细胞(RBC)输血和住院期间的短期耐受贫血。然而,与输血实践变化相关的长期结果尚未描述。
描述出院时及出院后贫血的患病率以及相关发病率和死亡率事件。
回顾性队列研究。
拥有 21 家医院的综合医疗服务系统,为 400 万成员提供服务。
2010 年 1 月至 2014 年 12 月期间存活的 445371 名成人,他们有 801261 次住院经历。
血红蛋白水平和 RBC 输血、再住院和出院后 6 个月内的死亡率事件。使用广义估计方程来观察随时间的趋势,同时考虑相关观察和患者水平的协变量。
从 2010 年到 2014 年,出院时中度贫血(血红蛋白水平在 7 到 10 g/dL 之间)的患病率从 20%增加到 25%(P<0.001),RBC 输血减少了 28%(39.8 至 28.5 RBC 单位/每 1000 名患者;P<0.001)。出院后 6 个月内中度贫血得到解决的患者比例从 42%下降到 34%(P<0.001),RBC 输血和出院后 6 个月内再住院的比例分别从 19%下降到 17%和从 37%下降到 33%(P<0.001)。在此期间,中度贫血患者的 6 个月死亡率从 16.1%下降到 15.6%(P=0.004),与其他所有患者的死亡率平行下降。
可能存在未测量的混杂因素。
住院后贫血的发生率与 RBC 输血的减少呈平行增加。这种增加并没有伴随着随后 6 个月内 RBC 使用、再住院或死亡率的上升。纵向分析支持限制 RBC 输血和耐受住院期间及之后贫血的实践建议的安全性。
美国国家心肺血液研究所。